Go Deep
Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,524 | 8.2 | 2.14 | 0.39 | 1,178.04 |
Sumitomo Pharma Co., Ltd. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 12,950,000,000.0 | 105,548,000,000.0 | 120,624,000,000.0 | 119,120,000,000.0 |
| Net Profit | 0.0 | -812,000,000.0 | 8,817,000,000.0 | 87,654,000,000.0 |
| EPS | — | — | — | — |
Sumitomo Pharma Co., Ltd. Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 453,294,000,000.0 | 398,832,000,000.0 | 314,558,000,000.0 | 555,544,000,000.0 | — |
| Net Profit | 106,865,000,000.0 | 23,634,000,000.0 | -314,969,000,000.0 | -74,512,000,000.0 | — |
| EPS | 269.0 | 59.5 | -792.8 | -187.6 | — |
Sumitomo Pharma Co., Ltd. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 804,571,000,000.0 | 742,604,000,000.0 | 907,506,000,000.0 | 1,134,742,000,000.0 | — |
| Total Liabilities | 512,104,000,000.0 | 573,125,000,000.0 | 751,370,000,000.0 | 727,960,000,000.0 | — |
| Total Equity | 292,467,000,000.0 | 169,479,000,000.0 | 156,063,000,000.0 | 406,749,000,000.0 | — |
Sumitomo Pharma Co., Ltd. Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 6.2%Receivables 16.3%Inventory 10.6%Fixed assets (tangible) 5.5%Intangible assets 46.2%Long-term investments 4.5%Other assets 10.7%
How it's funded — Mar 2026
Short-term debt 4.7%Long-term debt 22.3%Payables 7.0%Other liabilities 29.6%Shareholders' equity 36.4%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 49,637.0 | 39,956.0 | 36,132.0 | 163,652.0 |
| Receivables | 131,414.0 | 74,840.0 | 81,023.0 | 95,908.0 |
| Inventory | 85,414.0 | 94,222.0 | 115,350.0 | 94,405.0 |
| Fixed assets (tangible) | 44,231.0 | 46,648.0 | 57,895.0 | 58,909.0 |
| Intangible assets | 371,572.0 | 369,915.0 | 395,435.0 | 538,729.0 |
| Long-term investments | 36,400.0 | 5,588.0 | 360.0 | 134,007.0 |
| Other assets | 85,903.0 | 111,435.0 | 221,311.0 | 49,132.0 |
| Liabilities & equity | ||||
| Short-term debt | 38,130.0 | 46,440.0 | 285,517.0 | 90,588.0 |
| Long-term debt | 179,056.0 | 258,982.0 | 133,367.0 | 244,128.0 |
| Payables | 56,698.0 | 38,544.0 | 67,720.0 | 52,141.0 |
| Other liabilities | 238,220.0 | 229,159.0 | 264,766.0 | 341,103.0 |
| Shareholders' equity | 292,467.0 | 169,479.0 | 156,136.0 | 406,782.0 |
| Net tangible assets | -79,105.0 | -200,436.0 | -239,372.0 | -131,980.0 |
Sumitomo Pharma Co., Ltd. Cash Flow
| Line Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Operating Activities | 16,500,000,000.0 | -241,893,000,000.0 | 11,937,000,000.0 | 31,239,000,000.0 |
| Investing Activities | 99,754,000,000.0 | 33,036,000,000.0 | 52,419,000,000.0 | -18,278,000,000.0 |
| Financing Activities | -108,836,000,000.0 | 77,851,000,000.0 | -146,817,000,000.0 | -21,426,000,000.0 |